Delivery Order SPE2DX22D0049-SPE2D825FB1ED

The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $8,593.72 to AmerisourceBergen Drug Corp (UEI: KABZK8W6PQT3) on September 15, 2025, with an ultimate completion date of September 16, 2025. This firm fixed price, non-set-aside contract represents a child order issued under AmerisourceBergen's larger indefinite delivery contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen supplies a comprehensive range of pharmaceutical products and medical supplies to federal medical procurement needs, including brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains supporting military and veteran healthcare systems.

This delivery order is part of AmerisourceBergen's extensive portfolio of competitively awarded federal medical supply contracts. The company's DLA prime contract demonstrates its capability to fulfill federal procurement requirements through open competition, with delivery orders consistently structured as firm fixed price arrangements. The pharmaceutical prime vendor arrangement enables AmerisourceBergen to serve multiple government customers, including the Defense Health Agency and U.S. Coast Guard, providing flexible and comprehensive medical supply support on a global scale to sustain military healthcare programs and operations.